Browsing by Author "Cole AO"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    How can global guidelines support sustainable hygiene systems?
    (2023-Oct) Esteves Mills J; Thomas A; Abdalla N; El-Alam R; Al-Shabi K; Ashinyo ME; Bangoura FO; Charles K; Chipungu J; Cole AO; Engebretson B; Goyol K; Grasham CF; Grossi V; Hickling S; Kalandarov S; Ababu AK; Kholmuhammad K; Klaesener-Metzner N; Kugedera Z; Kwakye A; Lee-Llacer A; Maani PP; Makhafola B; Mohamed A; Monirul Alam M; Monse B; Northover H; Palomares A; Patabendi N; Paynter N; Prasad-Gautam O; Panthi SR; Rudge L; Saha S; Salaru I; Saltiel G; Sax L; Shahid MA; Gafur MS; Shrestha S; Szeberényi K; Tidwell JB; Trinies V; Yiha O; Ziganshin R; Gordon B; Cumming O; Water, Sanitation, Hygiene and Health Unit, Department of Environment, Climate Change and Health, World Health Organization (WHO), Geneva, Switzerland.; United Nations Children's Fund (UNICEF), New York, New York, USA.; Foreign Commonwealth & Development Office, Government of the United Kingdom, London, UK.; WHO Ghana Country Office, Accra, Ghana.; WHO Regional Office for the Eastern Mediterranean, Amman, Jordan.; Global Handwashing Partnership, Washington, District of Columbia, USA.; National Agency for Public Health, Government of the Republic of Moldova, Chisinau, Moldova (the Republic of).; WHO Ethiopia Country Office, Addis Ababa, Ethiopia.; World Vision International, Washington, District of Columbia, USA.; UNICEF Regional Office for South Asia, Kathmandu, Nepal.; WHO Country Office, Conakry, Guinea.; Health Emergency Interventions, WHO, Geneva, Switzerland.; Department of Public Health Engineering, Government of Bangladesh, Dhaka, Bangladesh.; Global Consultant, London, UK.; Environmental Health, World Health Organization, Kathmandu, Nepal.; Centre for Infectious Disease Research, Zambia (CIDRZ), Lusaka, Zambia.; UNICEF Nepal Country Office, Lalitpur, Nepal.; London School of Hygiene and Tropical Medicine, London, UK.; Ministry of Health & Social Protection, Government of Tajikistan, Dushanbe, Tajikistan.; Department of Health, Government of the Philippines, Manila, Philippines.; UNICEF Bangladesh Country Office, Dhaka, Bangladesh.; Department of Quality Assurance, Ghana Health Service, Accra, Ghana.; National Center for Public Health, Government of Hungary, Budapest, Hungary.; WHO Tajikistan Country Office, Dushanbe, Tajikistan.; UNICEF Pakistan Country Office, Lahore, Pakistan.; WaterAid, London, UK.; WHO Country Office, Sana'a, Yemen.; UNICEF Regional Office for East and Southern Africa, Nairobi, Kenya.; Water, Sanitation, Hygiene and Health Unit, Department of Environment, Climate Change and Health, World Health Organization (WHO), Geneva, Switzerland jestevesmills@gmail.com.; Department of Public Health, Ministry of Health, Funafuti, Tuvalu.; Ministry of Health, Government of South Africa, Pretoria, South Africa.; IRC India, New Delhi, India.; UNICEF Sri Lanka Country Office, Colombo, Sri Lanka.; UNICEF Tajikistan Country Office, Dushanbe, Tajikistan.; University of Oxford, Oxford, UK.; European Centre for Environment & Health, WHO Regional Office for Europe, Bonn, Germany.; WHO Iraq Country Office, Baghdad, Iraq.; German Agency for International Cooperation, Bonn, Germany.; World Bank, Washington, District of Columbia, USA.; UNICEF Ethiopia Country Office, Addis Ababa, Ethiopia.; Ministry of Health, Government of Ethiopia, Addis Ababa, Ethiopia.; WHO Bangladesh Country Office, Dhaka, Bangladesh.; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Thumbnail Image
    Item
    Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya.
    (2015-Apr-28) Hodgson SH; Juma E; Salim A; Magiri C; Njenga D; Molyneux S; Njuguna P; Awuondo K; Lowe B; Billingsley PF; Cole AO; Ogwang C; Osier F; Chilengi R; Hoffman SL; Draper SJ; Ogutu B; Marsh K; Sanaria Inc, Rockville, MD, USA. shoffman@sanaria.com.; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya. omandi.cole@gmail.com.; Kenya Medical Research Institute - Wellcome Trust, Centre for Geographical Medical Research (Coast), Kilifi, Kenya. COgwang@kemri-wellcome.org.; Kenya Medical Research Institute - Wellcome Trust, Centre for Geographical Medical Research (Coast), Kilifi, Kenya. blowe@kemri-wellcome.org.; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya. bernhards.ogutu@indepth-network.org.; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya. eajuma@kemri.org.; The Jenner Institute, University of Oxford, Oxford, UK. simon.draper@ndm.ox.ac.uk.; Kenya Medical Research Institute - Wellcome Trust, Centre for Geographical Medical Research (Coast), Kilifi, Kenya. patwnju@yahoo.co.uk.; Sanaria Inc, Rockville, MD, USA. pbillingsley@sanaria.com.; Centre for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya. eajuma@kemri.org.; Centre for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya. omandi.cole@gmail.com.; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya. charles.magiri@usamru-k.org.; Centre for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya. bernhards.ogutu@indepth-network.org.; Kenya Medical Research Institute - Wellcome Trust, Centre for Geographical Medical Research (Coast), Kilifi, Kenya. fosier@kemri-wellcome.org.; The Jenner Institute, University of Oxford, Oxford, UK. Susanne.hodgson@ndm.ox.ac.uk.; Kenya Medical Research Institute - Wellcome Trust, Centre for Geographical Medical Research (Coast), Kilifi, Kenya. smolyneux@kemri-wellcome.org.; Kenya Medical Research Institute - Wellcome Trust, Centre for Geographical Medical Research (Coast), Kilifi, Kenya. asalim@kemri-wellcome.org.; Kenya Medical Research Institute - Wellcome Trust, Centre for Geographical Medical Research (Coast), Kilifi, Kenya. kevin.marsh@ndm.ox.ac.uk.; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya. danielnjengah@yahoo.com.; Kenya Medical Research Institute - Wellcome Trust, Centre for Geographical Medical Research (Coast), Kilifi, Kenya. kawuondo@kemri-wellcome.org.; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. Roma.Chilengi@cidrz.org.; CIDRZ; Centre for Infectious Disease Research in Zambia (CIDRZ)
    BACKGROUND: Controlled human malaria infection (CHMI) studies, in which healthy volunteers are infected with Plasmodium falciparum to assess the efficacy of novel malaria vaccines and drugs, have become a vital tool to accelerate vaccine and drug development. CHMI studies provide a cost-effective and expeditious way to circumvent the use of large-scale field efficacy studies to deselect intervention candidates. However, to date few modern CHMI studies have been performed in malaria-endemic countries. METHODS: An open-label, randomized pilot CHMI study was conducted using aseptic, purified, cryopreserved, infectious P. falciparum sporozoites (SPZ) (Sanaria® PfSPZ Challenge) administered intramuscularly (IM) to healthy Kenyan adults (n = 28) with varying degrees of prior exposure to P. falciparum. The purpose of the study was to establish the PfSPZ Challenge CHMI model in a Kenyan setting with the aim of increasing the international capacity for efficacy testing of malaria vaccines and drugs, and allowing earlier assessment of efficacy in a population for which interventions are being developed. This was part of the EDCTP-funded capacity development of the CHMI platform in Africa. DISCUSSION: This paper discusses in detail lessons learnt from conducting the first CHMI study in Kenya. Issues pertinent to the African setting, including community sensitization, consent and recruitment are considered. Detailed reasoning regarding the study design (for example, dose and route of administration of PfSPZ Challenge, criteria for grouping volunteers according to prior exposure to malaria and duration of follow-up post CHMI) are given and changes other centres may want to consider for future studies are suggested. CONCLUSIONS: Performing CHMI studies in an African setting presents unique but surmountable challenges and offers great opportunity for acceleration of malaria vaccine and drug development. The reflections in this paper aim to aid other centres and partners intending to use the CHMI model in Africa.